Obesity, hyperlipidemia, and metabolic syndrome

Liver Transplantation

Volumn 15, Issue SUPPL. 2, 2009, Pages

  Charlton, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; IMMUNOSUPPRESSIVE AGENT; OMEGA 3 FATTY ACID; PRAVASTATIN; SIMVASTATIN; STEROID;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIETARY FIBER; DIETARY INTAKE; DYSLIPIDEMIA; FRUIT; GRAFT FAILURE; GRAFT RECIPIENT; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MEDITERRANEAN DIET; METABOLIC SYNDROME X; OBESITY; ORGAN DONOR; PRIORITY JOURNAL; RENAL PROTECTION; TREATMENT OUTCOME; VEGETABLE; WEIGHT REDUCTION; DIET THERAPY; HUMAN; LONG TERM CARE; RISK FACTOR;

HUMANS; HYPERLIPIDEMIAS; LIVER TRANSPLANTATION; LONG-TERM CARE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; TREATMENT OUTCOME;

EID: 77449089452     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21914     Document Type: Article

References (26)

1. Sturm R,. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003; 163: 2146-2148. (Pubitemid 37248778)
2. Flancbaum L, Choban PS,. Surgical implications of obesity. Annu Rev Med 1998; 49: 215-234. (Pubitemid 28197451)
3. Nair S, Verma S, Thuluvath PJ,. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-109. (Pubitemid 34032549)
4. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M,. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667-672. (Pubitemid 351287533)
5. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-1243. (Pubitemid 37536793)
6. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
7. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res 1998; 6 (suppl 2): 51S-209S.
8. Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, Holdaas H,. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787-1792. (Pubitemid 33144233)
9. Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500. (Pubitemid 36306867)
10. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005; 37: 4416-4423. (Pubitemid 43016046)
11. Clark JM,. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: S5-S10. (Pubitemid 44309537)
12. Angulo P,. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006; 12: 523-534. (Pubitemid 43780662)
13. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH,. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998; 4: 285-296. (Pubitemid 28323748)
14. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114. (Pubitemid 47305029)
15. Boden G,. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM [published correction appears in Diabetes 1997;46:536]. Diabetes 1997; 46: 3-10.
16. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Papachristodoulou A, Kostakis AI,. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol 2006; 38: 343-348. (Pubitemid 44138164)
17. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J,. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009; 9: 782-793.
18. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-614. (Pubitemid 32677885)
19. Maor-Kendler Y, Batts KP, Burgart LJ, Wiesner RH, Krom RA, Rosen CB, Charlton MR,. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000; 70: 292-297. (Pubitemid 30602745)
20. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373. (Pubitemid 32331542)
21. Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007; 13: 844-847. (Pubitemid 46947849)
22. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107. (Pubitemid 27357062)
23. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429. (Pubitemid 47344777)
24. Nair S, Cohen DB, Cohen MP, Tan H, Maley W, Thuluvath PJ,. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001; 96: 842-845. (Pubitemid 32240742)
25. Duchini A, Brunson ME,. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001; 72: 156-159. (Pubitemid 32652522)
26. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521-1531. (Pubitemid 350168192)